المؤلفون: Pedersen, Mette Abildgaard, Gormsen, Lars C, Jakobsen, Lasse H, Eyre, Toby A, Severinsen, Marianne T, Baech, Joachim, Dann, Eldad J, Knapp, Andrea, Sahin, Denis, Vestergaard, Peter, El-Galaly, Tarec C, Jensen, Paw

المصدر: Pedersen , M A , Gormsen , L C , Jakobsen , L H , Eyre , T A , Severinsen , M T , Baech , J , Dann , E J , Knapp , A , Sahin , D , Vestergaard , P , El-Galaly , T C & Jensen , P 2024 , ' The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study ' , British Journal of Haematology , vol. 204 , no. 4 , pp. 1271-1278 . https://doi.org/10.1111/bjh.19194Test

مصطلحات موضوعية: CHOP, chemotherapy, clinical studies, late effects of therapy, non-Hodgkin lymphoma, Bone Density, Fractures, Compression/drug therapy, Humans, Middle Aged, Bendamustine Hydrochloride/adverse effects, Lymphoma, Follicular/drug therapy, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Prednisone/adverse effects, Vincristine/adverse effects, Rituximab/adverse effects, Spinal Fractures/drug therapy

الوصف: Standard CHOP treatment includes a high cumulative dose of prednisone, and studies have shown increased fracture risk following CHOP. It is unclear whether reductions in bone mineral density (BMD) are caused by glucocorticoids or by the combination with chemotherapy. Our objective was to determine the effect of obinutuzumab (G)/rituximab (R)-bendamustine versus G/R-CHOP on BMD in follicular lymphoma patients. Patients in this GALLIUM post hoc study were ≥60 years old and in complete remission at induction treatment completion (ITC), following treatment with G or R in combination with bendamustine or CHOP. To assess BMD, Hounsfield units (HU) were measured in lumbar vertebra L1 on annual computed tomography. Furthermore, vertebral compression fractures were recorded. Of 173 patients included, 59 (34%) received CHOP and 114 (66%) received bendamustine. At baseline, there was no difference in HU between groups. The mean HU decrease from baseline to ITC was 27.8 after CHOP and 17.3 after bendamustine, corresponding to a difference of 10.4 (95% CI: 3.2-17.6). Vertebral fractures were recorded in 5/59 patients receiving CHOP and in 2/114 receiving bendamustine. CHOP was associated with a significant greater decrease in BMD and more frequent fractures. These results suggest that prophylaxis against BMD loss should be considered.

العلاقة: https://pure.au.dk/portal/en/publications/c35bd821-3220-460c-a53c-62ee77c32693Test

الإتاحة: https://doi.org/10.1111/bjh.19194Test
https://pure.au.dk/portal/en/publications/c35bd821-3220-460c-a53c-62ee77c32693Test

المؤلفون: Pedersen, Mette Abildgaard, Gormsen, Lars C., Jakobsen, Lasse H., Eyre, Toby A., Severinsen, Marianne T., Baech, Joachim, Dann, Eldad J., Knapp, Andrea, Sahin, Denis, Vestergaard, Peter, El-Galaly, Tarec C., Jensen, Paw

المصدر: Pedersen , M A , Gormsen , L C , Jakobsen , L H , Eyre , T A , Severinsen , M T , Baech , J , Dann , E J , Knapp , A , Sahin , D , Vestergaard , P , El-Galaly , T C & Jensen , P 2024 , ' The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study ' , British Journal of Haematology , vol. 204 , no. 4 , pp. 1271-1278 . https://doi.org/10.1111/bjh.19194Test

مصطلحات موضوعية: chemotherapy, CHOP, clinical studies, late effects of therapy, non-Hodgkin lymphoma, Bone Density, Fractures, Compression/drug therapy, Humans, Middle Aged, Bendamustine Hydrochloride/adverse effects, Lymphoma, Follicular/drug therapy, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Prednisone/adverse effects, Vincristine/adverse effects, Rituximab/adverse effects, Spinal Fractures/drug therapy

الوصف: Standard CHOP treatment includes a high cumulative dose of prednisone, and studies have shown increased fracture risk following CHOP. It is unclear whether reductions in bone mineral density (BMD) are caused by glucocorticoids or by the combination with chemotherapy. Our objective was to determine the effect of obinutuzumab (G)/rituximab (R)-bendamustine versus G/R-CHOP on BMD in follicular lymphoma patients. Patients in this GALLIUM post hoc study were ≥60 years old and in complete remission at induction treatment completion (ITC), following treatment with G or R in combination with bendamustine or CHOP. To assess BMD, Hounsfield units (HU) were measured in lumbar vertebra L1 on annual computed tomography. Furthermore, vertebral compression fractures were recorded. Of 173 patients included, 59 (34%) received CHOP and 114 (66%) received bendamustine. At baseline, there was no difference in HU between groups. The mean HU decrease from baseline to ITC was 27.8 after CHOP and 17.3 after bendamustine, corresponding to a difference of 10.4 (95% CI: 3.2–17.6). Vertebral fractures were recorded in 5/59 patients receiving CHOP and in 2/114 receiving bendamustine. CHOP was associated with a significant greater decrease in BMD and more frequent fractures. These results suggest that prophylaxis against BMD loss should be considered.

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/0e52bb84-d887-4010-93f8-16876be6a456Test

الإتاحة: https://doi.org/10.1111/bjh.19194Test
https://portal.findresearcher.sdu.dk/da/publications/0e52bb84-d887-4010-93f8-16876be6a456Test
https://findresearcher.sdu.dk/ws/files/259570075/Br_J_Haematol_-_2023_-_Pedersen_-_The_impact_of_CHOP_versus_bendamustine_on_bone_mineral_density_in_patients_with_indolent.pdfTest

المساهمون: Moon Chul Lee, Taick Sang Nam, Se Jung Jung, Young S. Gwak, JoongWoo Leem, Leem, Joong Woo, Jung, Se Jung

المصدر: T201503890.pdf

مصطلحات موضوعية: Animals, Behavior, Animal/drug effects, Benzylamines/therapeutic use, Bicuculline/therapeutic use, GABA Antagonists/therapeutic use, GABA-A Receptor Antagonists/therapeutic use, GABA-B Receptor Antagonists/therapeutic use, Ganglia, Spinal/physiopathology, Hindlimb/innervation, Hindlimb/pathology, Hyperalgesia/drug therapy, Hyperalgesia/etiology, Hyperalgesia/physiopathology, Male, Pain Measurement/drug effects, Phosphinic Acids/therapeutic use, Rats, Sprague-Dawley, Spinal Cord/physiopathology, Spinal Cord Compression/drug therapy, Spinal Cord Compression/etiology, Spinal Cord Compression/physiopathology, gamma-Aminobutyric Acid/metabolism

الوصف: Chronic compression of dorsal root ganglion (CCD) results in neuropathic pain. We investigated the role of spinal GABA in CCD-induced pain using rats with unilateral CCD. A stereological analysis revealed that the proportion of GABA-immunoreactive neurons to total neurons at L4/5 laminae I-III on the injured side decreased in the early phase of CCD (post-CCD week 1) and then returned to the sham-control level in the late phase (post-CCD week 18). In the early phase, the rats showed an increase in both mechanical sensitivity of the hind paw and spinal WDR neuronal excitability on the injured side, and such increase was suppressed by spinally applied muscimol (GABA-A agonist, 5�뎝mol) and baclofen (GABA-B agonist, 25�뎝mol), indicating the reduced spinal GABAergic inhibition involved. In the late phase, the CCD-induced increase in mechanical sensitivity and neuronal excitability returned to pre-CCD levels, and such recovered responses were enhanced by spinally applied bicuculline (GABA-A antagonist, 15�뎝mol) and CGP52432 (GABA-B antagonist, 15�뎝mol), indicating the regained spinal GABAergic inhibition involved. In conclusion, the alteration of spinal GABAergic inhibition following CCD and leading to a gradual reduction over time of CCD-induced mechanical hypersensitivity is most likely due to changes in GABA content in spinal GABA neurons. ; open

وصف الملف: application/pdf

العلاقة: NEURAL PLASTICITY; J02319; OAK-2015-02267; https://ir.ymlib.yonsei.ac.kr/handle/22282913/141427Test; T201503890; NEURAL PLASTICITY, Vol.2015 : 924728, 2015

الإتاحة: https://doi.org/10.1155/2015/924728Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/141427Test

المساهمون: Kyung Soo Suk, Hwan Mo Lee, Seong Hwan Moon, Hee June Kim, Hak Sun Kim, Jin Oh Park, Byung Ho Lee, Kim, Hak Sun, Moon, Seong Hwan, Park, Jin Oh, Suk, Kyung Soo, Lee, Hwan Mo

المصدر: T201404481.pdf

مصطلحات موضوعية: Aged, 80 and over, Bone Density/drug effects, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/pharmacology, Cohort Studies, Drug Administration Schedule, Female, Fractures, Compression/drug therapy, Compression/etiology, Humans, Incidence, Male, Middle Aged, Osteoporosis/complications, Osteoporotic Fractures/drug therapy, Osteoporotic Fractures/etiology, Retrospective Studies, Spinal Fractures/drug therapy, Spinal Fractures/etiology, Teriparatide/administration & dosage, Teriparatide/pharmacology, Time Factors, Treatment Outcome, Osteoporosis, duration, teriparatide, vertebral compression fracture

الوصف: PURPOSE: Teriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M). MATERIALS AND METHODS: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272). RESULTS: The group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006). CONCLUSION: At least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy. ; open

وصف الملف: 1576~1583

العلاقة: YONSEI MEDICAL JOURNAL; J02813; OAK-2014-02641; https://ir.ymlib.yonsei.ac.kr/handle/22282913/138374Test; T201404481; YONSEI MEDICAL JOURNAL, Vol.55(6) : 1576-1583, 2014

الإتاحة: https://doi.org/10.3349/ymj.2014.55.6.1576Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138374Test

المؤلفون: Fehlings, Michael G, Badhiwala, Jetan H, Ahn, Henry, Farhadi, H Francis, Shaffrey, Christopher I, Nassr, Ahmad, Mummaneni, Praveen, Arnold, Paul M, Jacobs, W Bradley, Riew, K Daniel, Kelly, Michael, Brodke, Darrel S, Vaccaro, Alexander R, Hilibrand, Alan S, Wilson, Jason D

المصدر: School of Medicine Faculty Publications

مصطلحات موضوعية: Adolescent, Adult, Aged, 80 and over, Cervical Vertebrae/surgery, Combined Modality Therapy, Decompressive Craniectomy/methods, Double-Blind Method, Endpoint Determination, Female, Humans, Intervertebral Disc Degeneration/drug therapy/surgery, Male, Middle Aged, Neuroprotective Agents/adverse effects/therapeutic use, Neurosurgical Procedures/methods, Pain, Postoperative/epidemiology, Riluzole/adverse effects/therapeutic use, Spinal Cord Compression/drug therapy/surgery, Treatment Outcome, Medicine and Health Sciences

العلاقة: https://digitalscholar.lsuhsc.edu/som_facpubs/1227Test; https://doi.org/10.1016/S1474-4422Test(20)30407-5

الإتاحة: https://doi.org/10.1016/S1474-4422Test(20)30407-5
https://digitalscholar.lsuhsc.edu/som_facpubs/1227Test

المساهمون: Eun Yeong Choe, Je Eun Song, Kyeong Hye Park, Hannah Seok, Eun Jig Lee, Sung-Kil Lim, Yumie Rhee, Park, Kyeong Hye, Seok, Hannah, Song, Je Eun, Rhee, Yumie, Lee, Eun Jig, Lim, Sung Kil, Choe, Eun Yeong

مصطلحات موضوعية: Adult, Back Pain/etiology, Bone Density/drug effects, Calcium Carbonate/therapeutic use, Cholecalciferol/therapeutic use, Diphosphonates/adverse effects, Female, Femur Neck/drug effects, Fractures, Compression/drug therapy, Compression/pathology, Humans, Lactation/physiology, Osteoporosis/drug therapy, Osteoporosis/pathology, Parathyroid Hormone/therapeutic use, Pregnancy, Pregnancy Complications/drug therapy, Pregnancy Complications/pathology, Spinal Fractures/drug therapy, Spinal Fractures/pathology, Teriparatide/therapeutic use, Lactation, Osteoporosis, Teriparatide

الوصف: Pregnancy and lactation-associated osteoporosis (PLO) is very rare, but it can cause severe vertebral compression fractures with disabling back pain. PLO patients have commonly been treated with antiresorptive agents against high bone turnover. There are, however, some concerns regarding the use of bisphosphonates: (1) PLO occurs during the first pregnancy with a high possibility of recurrence during the second pregnancy, (2) long-term outcomes of bisphosphonates in PLO are lacking, and (3) there is a possibility of bisphosphonates accumulated in the bones crossing the placenta. Therefore, alternative therapies must be considered. We analyzed the effect of teriparatide (TPTD), the human recombinant parathyroid hormone (1-34), for 18 months in three women with PLO. Multiple vertebral fractures with severe back pain appeared within 6 months after their first childbirth. Two of them had a family history of osteoporosis. Lactation was discontinued immediately after diagnosis of PLO. Calcium carbonate, cholecalciferol, and TPTD were prescribed. The back pain immediately resolved. Bone mineral density (BMD) increased by 14.5-25.0% (mean 19.5%) at the lumbar spine and by 9.5-16.7% (mean 13.1%) at the femoral neck, after 18 months of treatment. The final Z scores in these PLO patients were nearly normalized. Two women had a second baby without any complication. BMD significantly improved after 18 months of treatment with TPTD without further fractures. In conclusion, TPTD should be considered to avoid long-term morbidity in young patients with PLO and is highly encouraged for use in PLO patients with multiple vertebral fractures. ; open

العلاقة: JOURNAL OF BONE AND MINERAL METABOLISM; J01277; OAK-2012-01810; https://ir.ymlib.yonsei.ac.kr/handle/22282913/90636Test; http://link.springer.com/article/10.1007%2Fs00774-011-0334-0Test; T201203327; JOURNAL OF BONE AND MINERAL METABOLISM, Vol.30(5) : 596-601, 2012

الإتاحة: https://ir.ymlib.yonsei.ac.kr/handle/22282913/90636Test